Smith Salley Wealth Management Boosts Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Smith Salley Wealth Management increased its stake in Thermo Fisher Scientific by 2.5%, holding 57,075 shares valued at approximately $23.14 million, making it the firm's 23rd largest position.
• Multiple institutional investors, including Vanguard and Amundi, have also raised their stakes in Thermo Fisher Scientific, indicating strong interest from major players in the company's stock.
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43, with a yield of 0.4%, reinforcing the company’s commitment to returning value to shareholders.

Smith Salley Wealth Management raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,075 shares of the medical research company's stock after purchasing an additional 1,415 shares during the period. Thermo Fisher Scientific comprises 1.3% of Smith Salley Wealth Management's portfolio, making the stock its 23rd biggest position. Smith Salley Wealth Management's holdings in Thermo Fisher Scientific were worth $23,141,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of TMO. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Amundi boosted its stake in Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA lifted its holdings in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after purchasing an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last quarter. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on TMO. Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. William Blair assumed coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $588.35.

Thermo Fisher Scientific Trading Up 1.1%

Shares of TMO opened at $464.18 on Friday. The company has a 50 day simple moving average of $476.70 and a two-hundred day simple moving average of $447.57. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $175.28 billion, a P/E ratio of 26.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.